Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Oncogene|March 13, 1997
The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomachH Nakagawa, T C Wang, L Zukerberg, et al.
The American Journal of Gastroenterology|January 11, 2001
Clinical experience with infliximab therapy in 100 patients with Crohn's diseaseR J Farrell, S A Shah, P J Lodhavia, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1995
5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cellsC Stevens, M Lipman, S Fabry, et al.
Pancreas|January 1, 1996
Ki-ras and p53 mutations in pancreatic ductal adenocarcinomaC J Rall, Y X Yan, F Graeme-Cook, et al.
Molecular Vision|September 13, 2000
Ultrastructural and ERG findings in mice with adenomatous polyposis coli gene disruptionD M Marcus, A K Rustgi, D Defoe, et al.
Oncogene|February 2, 1999
Cyclin D1 overexpression combined with N-nitrosomethylbenzylamine increases dysplasia and cellular proliferation in murine esophageal squamous epitheliumT D Jenkins, A Mueller, R Odze, et al.
Inflammatory Bowel Diseases|January 4, 2013
Enhanced intramucosal cytotoxic lymphocyte gene expression in ulcerative colitisA C Stevens, M L Lipman, J E Spivack, et al.
Gastroenterology|May 1, 1993
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study GroupJ W Singleton, S B Hanauer, G L Gitnick, et al.
Cancer Letters|November 6, 1995
Peritoneal exfoliative cytology and Ki-ras mutational analysis in patients with pancreatic adenocarcinomaC J Rall, J A Rivera, B A Centeno, et al.
Digestive Diseases and Sciences|June 1, 1992
Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel diseaseC Stevens, G Walz, C Singaram, et al.
Pageof 13